Literature DB >> 18309177

Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics.

José M Ferro1, Patrícia Canhão, Marie-Germaine Bousser, Jan Stam, Fernando Barinagarrementeria.   

Abstract

BACKGROUND AND
PURPOSE: The risk of seizure early after the diagnosis of cerebral vein and dural sinus thrombosis (CVT) is not known, and the use of prophylactic antiepileptic (AED) medication in the acute phase of CVT is controversial.
METHODS: In a multicenter, prospective, observational study, we analyzed the risk factors for seizures experienced before the diagnosis of CVT was confirmed (presenting seizures) or within the following 2 weeks (early seizures). The risk of occurrence of early seizures was compared in 4 risk strata and related to whether patients received AEDs or not. Criteria for the strata were "presenting seizures" and "supratentorial lesions."
RESULTS: Two hundred forty-five of 624 (39.3%) patients with CVT experienced presenting seizures, and 43 (6.9%) patients had early seizure. In logistic-regression analysis, supratentorial lesion (odds ratio [OR]=4.05, 95% CI=2.74 to 5.95), cortical vein thrombosis (OR=2.31, 95% CI=1.44 to 3.73), sagittal sinus thrombosis (OR=2.18, 95% CI=1.50 to 3.18), and puerperal CVT (OR=2.06, 95% CI=1.19 to 3.55) were associated with presenting seizures, whereas supratentorial lesion (OR=3.09, 95% CI=1.56 to 9.62) and presenting seizures (OR=1.74, 95% CI=0.90 to 3.37) predicted early seizures. The risk of early seizures in patients with supratentorial lesions and presenting seizures was significantly lower when AED prophylaxis was used (1 with seizures in 148 patients with AEDs vs 25 in 47 patients without AEDs; OR=0.006, 95% CI=0.001 to 0.05).
CONCLUSIONS: CVT patients with supratentorial lesions had a higher risk for both presenting and early seizures, whereas patients with presenting seizures had a higher risk of recurrent seizures within 2 weeks. Our results support the prescription of AEDs in acute CVT patients with supratentorial lesions who present with seizures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309177     DOI: 10.1161/STROKEAHA.107.487363

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  39 in total

1.  Persistent headache after earache.

Authors:  Anita Au; Mahdiya Al Bulushi; Mashel Al Rajub; Suzanne Morin
Journal:  CMAJ       Date:  2010-09-13       Impact factor: 8.262

2.  Cerebral Venous Thrombosis and Its Clinical Diversity.

Authors:  Giovana Ennis; Nelson Domingues; Joana Silva Marques; Pedro Ribeiro; Cristina Andrade
Journal:  Cureus       Date:  2021-04-29

Review 3.  [Epileptic seizures and epilepsy after a stroke : Incidence, prevention and treatment].

Authors:  F Benninger; M Holtkamp
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

Review 4.  Cerebral Venous Thrombosis: an Update.

Authors:  José M Ferro; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-23       Impact factor: 5.081

Review 5.  Managing unusual presentations of venous thromboembolism.

Authors:  Walter Ageno
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 6.  Cerebral venous thrombosis.

Authors:  Suzanne M Silvis; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Nat Rev Neurol       Date:  2017-08-18       Impact factor: 42.937

7.  Diagnosing deep cerebral venous thrombosis.

Authors:  Usaamah Mahmood Khan; Crystal S Janani; Marian P LaMonte
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-01-02

8.  Cerebral venous sinus thrombosis complicated by seizures.

Authors:  Halil Onder
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

9.  A study of factors associated with cerebral venous thrombosis.

Authors:  Mehdi Jalili; Shadi Ghourchian; Gholam Ali Shahidi; Mohammad Rohani; Mohammad Rezvani; Babak Zamani
Journal:  Neurol Sci       Date:  2012-03-07       Impact factor: 3.307

Review 10.  Cerebral vein thrombosis.

Authors:  Francesco Dentali; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.